dc.creator | Yardley, D.A. | es |
dc.creator | Coleman, R. | es |
dc.creator | Conte, P. | es |
dc.creator | Cortes, J. | es |
dc.creator | Brufsky, A. | es |
dc.creator | Shtivelband, M. | es |
dc.creator | Cruz Merino, Luis de la | es |
dc.creator | Harbeck, N. | es |
dc.date.accessioned | 2024-03-12T15:55:56Z | |
dc.date.available | 2024-03-12T15:55:56Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Yardley, D.A., Coleman, R., Conte, P., Cortes, J., Brufsky, A., Shtivelband, M.,...,Harbeck, N. (2018). nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of oncology, 29 (8), 1763-1770. https://doi.org/10.1093/annonc/mdy201. | |
dc.identifier.issn | 0923-7534 | es |
dc.identifier.issn | 1569-8041 | es |
dc.identifier.uri | https://hdl.handle.net/11441/156154 | |
dc.description.abstract | Background: Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course.
tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine
(nab-P/G), and gemcitabine plus carboplatin (G/C) in patients with mTNBC.
Patients and methods: Patients with pathologically confirmed mTNBC and no prior chemotherapy for metastatic BC received
(1 : 1 : 1) nab-P 125 mg/m2 plus C AUC 2, nab-P 125 mg/m2 plus G 1000 mg/m2
, or G 1000 mg/m2 plus C AUC 2, all on days 1, 8
q3w. Phase II primary end point: investigator-assessed progression-free survival (PFS); secondary end points included overall
response rate (ORR), overall survival (OS), percentage of patients initiating cycle 6 with doublet therapy, and safety.
Results: In total, 191 patients were enrolled (nab-P/C, n ¼ 64; nab-P/G, n ¼ 61; G/C, n ¼ 66). PFS was significantly longer with
nab-P/C versus nab-P/G [median, 8.3 versus 5.5 months; hazard ratio (HR), 0.59 [95% CI, 0.38–0.92]; P ¼ 0.02] or G/C (median, 8.3
versus 6.0 months; HR, 0.58 [95% CI, 0.37–0.90]; P ¼ 0.02). OS was numerically longer with nab-P/C versus nab-P/G (median, 16.8
versus 12.1 months; HR, 0.73 [95% CI, 0.47–1.13]; P ¼ 0.16) or G/C (median, 16.8 versus 12.6 months; HR, 0.80 [95% CI, 0.52–1.22];
P ¼ 0.29). ORR was 73%, 39%, and 44%, respectively. In the nab-P/C, nab-P/G, and G/C groups, 64%, 56%, and 50% of patients
initiated cycle 6 with a doublet. Grade 3 adverse events were mainly hematologic.
Conclusions: First-line nab-P/C was active in mTNBC and resulted in a significantly longer PFS and improved risk/benefit profile
versus nab-P/G or G/C. | es |
dc.format | application/pdf | es |
dc.format.extent | 8 p. | es |
dc.language.iso | eng | es |
dc.publisher | Oxford University Press | es |
dc.relation.ispartof | Annals of oncology, 29 (8), 1763-1770. | |
dc.rights | Attribution-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nd/4.0/ | * |
dc.subject | Chemotherapy | es |
dc.subject | Triple-negative breast cancer | es |
dc.subject | Nab-paclitaxel | es |
dc.subject | Gemcitabine | es |
dc.title | nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S0923753419341225?via%3Dihub | es |
dc.identifier.doi | 10.1093/annonc/mdy201 | es |
dc.contributor.group | Universidad de Sevilla. CTS151: Bioquímica médica. | es |
dc.journaltitle | Annals of oncology | es |
dc.publication.volumen | 29 | es |
dc.publication.issue | 8 | es |
dc.publication.initialPage | 1763 | es |
dc.publication.endPage | 1770 | es |